Cancer prevention

Cancer

Durable Responses and Improved Survival in Patients with Relapsed or Refractory Large B-Cell Lymphoma Demonstrated by Autologous CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Researchers at the H. Lee Moffitt Cancer Center have reported single-cell RNA sequencing (scRNA-seq) data on 57 pre-infusion CAR T-cell products from axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) patients treated as standard-of-care for relapsed or refractory large B-cell lymphoma (R/R LBCL). The study found that axi-cel is comprised of